2022 American Transplant Congress
Chronic Active Antibody Mediated Rejection: 3 Month Response Rates to Treatment and Predictors of Graft Survival
University of Wisconsin, Madison, WI
*Purpose: There is limited information on effectiveness of treatment and predictors of graft survival following chronic active antibody mediated rejection (cABMR) in kidney transplant recipients…2022 American Transplant Congress
Implementing Genetic Testing in the Evaluation of the Kidney Transplant Candidate
*Purpose: To describe the incorporation of a genetic renal panel to improve the characterization of end stage kidney disease (ESKD) etiology in the kidney transplant…2022 American Transplant Congress
Measurement of Physical Activity and Frailty in the Early Post-Operative Period After Kidney Transplant-Single-Center Prospective Pilot Study Using Fitbit Watch
Henry Ford Transplant Institute, Detroit, MI
*Purpose: Physical activity monitors (PAMs) allow patients to track multiple health parameters. PAM’s may be helpful to assess a patient’s physical recovery after a Kidney…2022 American Transplant Congress
Mitochondrial Transplant as Novel Therapeutic Modality to Reduce Nonalcoholic Fatty Liver Disease
*Purpose: Mitochondrial dysfunction in adipose tissue is one of the mechanisms contributing to obesity and its co-morbidities. Transfer of healthy mitochondria has proven successful in…2022 American Transplant Congress
Neutrophil CEACAM1 Regulates Extracellular Trap Formation via Non-Canonical Inflammasome Signaling and Impacts Liver Transplantation in Mouse and Human
*Purpose: Neutrophil extracellular trap (NET) formation relates to various diseases, including sterile inflammation. Although neutrophils express proficient CEACAM1 (CC1, also known as CD66a) long isoform,…2022 American Transplant Congress
Lung Transplant Waitlist Outcomes for Blood Group O Candidates After the Expansion of the Primary Allocation Unit in November 2017
*Purpose: Blood group O is associated with decreased lung transplant rates. Occasionally, blood group donor O lungs are allocated to non-blood group O recipients. Since…2022 American Transplant Congress
Broad Panel Genetic Testing for Chronic Kidney Disease in the Transplant Center
*Purpose: Genetic testing is an emerging tool for the evaluation of patients with end-stage renal disease (ESRD). In kidney transplantation (KT), testing can identify disease…2022 American Transplant Congress
Absolute Quantification of Donor-Derived Cell-Free DNA Does Not Provide Additional Discriminating Power Over Donor-derived Cell-Free DNA Fraction for Detection of Allograft Rejection
*Purpose: High level of background cell-free DNA (cfDNA) has been hypothesized as a concern for false negative results in molecular diagnostics for allograft rejection that…2022 American Transplant Congress
The Perspective of General Nephrologists Toward Transitions of Care and Management of Patients with Failing Kidney Allografts
*Purpose: Failing kidney allograft with subsequent return to dialysis is associated with high risk of morbidity and mortality. This project aimed to examine general nephrologist…2022 American Transplant Congress
BK Polyomavirus Infection is Not Associated with a Meaningful Increase in Donor-Derived Cell-Free DNA
1Warren Alpert Medical School of Brown University, Providence, RI, 2CareDx, Brisbane, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive measure of early allograft injury that has been clinically validated as a surveillance tool to detect antibody…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 190
- Next Page »